Nanoparticle‐Mediated CXCL12–CXCR4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma
Advanced Science · 2025-08 · 12 (30)
DOI: 10.1002/advs.202500225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 19.06.2025. Verfasst von Qianqian Cao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, P. R. China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Receptors, CXCR4, Chemokine CXCL12, Nanoparticles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ceyuan Puhui (Ningbo) Biotechnology Co., Ltd., Medical Research Project of China Medical and Health Development Foundation.
Abstract (Originalsprache)
Gastric carcinoma (GC) remains a major global health challenge, requiring novel therapeutic approaches. This study investigates the efficacy of self‐assembled M2pep‐Cs NPs/Plerixafor nanoparticles in suppressing GC by targeting the CXCL12–CXCR4 signaling pathway and reprogramming tumor‐associated macrophages (TAMs) to enhance anti‐tumor immunity. The nanoparticles’ physicochemical properties and biocompatibility are assessed using transmission electron microscopy, dynamic light scattering, and biological assays. A GC mouse model is established, followed by histological and immunohistochemical analyses to evaluate tumor apoptosis and proliferation. Multi‐omics approaches, including transcriptomics, proteomics, and metabolomics, identify key genes and pathways affected by treatment. Flow cytometry and ELISA quantify immune activation markers; while, cell migration and invasion assays evaluate tumor suppression effects. The results demonstrate that M2pep‐Cs NPs/Plerixafor effectively modulates the tumor microenvironment, suppressing GC progression by reprogramming TAMs through CXCL12–CXCR4 inhibition, enhancing immune recognition and T cell responses. This study provides mechanistic insights and highlights the potential of nanoparticle‐based immunotherapy for GC, offering a promising avenue for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, P. R. China.
- Department of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, 266042, P. R. China.
- Postdoctoral workstation, Liaocheng People's Hospital, No. 67, Dongchang West Road, Liaocheng, 252000, P. R. China.
- Department of Spine Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, P. R. China.
- Tumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, P. R. China.
ORCID-Profile: Xiaomei Li
Förderung
- Ceyuan Puhui (Ningbo) Biotechnology Co., Ltd.
- Medical Research Project of China Medical and Health Development Foundation
Zitieren
APA
Cao, Q., Cheng, X., Lv, R., Sun, D., Wang, J., Fu, R., Gong, R., Xiao, Y., Liu, Q., & Li, X. (2025). Nanoparticle‐Mediated CXCL12–CXCR4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma. Advanced Science, 12(30). https://doi.org/10.1002/advs.202500225
Vancouver
Cao Q, Cheng X, Lv R, Sun D, Wang J, Fu R, et al. Nanoparticle‐Mediated CXCL12–CXCR4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma. Advanced Science. 2025;12(30). doi:10.1002/advs.202500225
BibTeX
@article{Cao2025,
author = {Cao, Qianqian and Cheng, Xiaolei and Lv, Rongbin and Sun, Dianshui and Wang, Jihua and Fu, Runjia and Gong, Rumei and Xiao, Yueying and Liu, Qin and Li, Xiaomei},
title = {Nanoparticle‐Mediated CXCL12–CXCR4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {30},
doi = {10.1002/advs.202500225}
}
EUVIMED